Proposal to Withdraw Approval; Notice of Opportunity for a Hearing for the Breast Cancer Indication for Bevacizumab (Avastin)

 
Docket ID: FDA-2010-N-0621
Agency: Food and Drug Administration (FDA)
Parent Agency: Department of Health and Human Services (HHS)
Docket Details open glossary dialog  
Related RINs: None
Related Dockets: None
Short Title: Proposal to Withdraw Marketing Approval for Bevacizumab (Avastin); Notice of Opportunity for a Hearing
Keyword(s): CDER, Avastin, bevacizumab
Type: Nonrulemaking
Docket Status: OPEN
Center: CDER
Docket Item Code: N
 

Primary Documents

View All  (82)
Comment Period Closed
Aug 04, 2011 11:59 PM ET
Notice
Posted: 05/11/2011
ID: FDA-2010-N-0621-0143
Comment Period Closed
Notice
Posted: 02/27/2012
ID: FDA-2010-N-0621-0545
Comment Period Closed
Other
Posted: 11/21/2011
ID: FDA-2010-N-0621-0544
Comment Period Closed
Other
Posted: 11/03/2011
ID: FDA-2010-N-0621-0537
Comment Period Closed
Other
Posted: 11/03/2011
ID: FDA-2010-N-0621-0538

Supporting Documents

View All  (9)
Comments Not Accepted
Supporting & Related Material
Posted: 05/31/2011
ID: FDA-2010-N-0621-0156
Comments Not Accepted
Supporting & Related Material
Posted: 05/16/2011
ID: FDA-2010-N-0621-0145
Comments Not Accepted
Supporting & Related Material
Posted: 02/23/2011
ID: FDA-2010-N-0621-0052

Comments

View All  (454)

561
Comments Received*
*This count refers to the total comment/submissions received on this docket, as of 11:59 PM yesterday. Note: Agencies review all submissions, however some agencies may choose to redact, or withhold, certain submissions (or portions thereof) such as those containing private or proprietary information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. This can result in discrepancies between this count and those displayed when conducting searches on the Public Submission document type. For specific information about an agency’s public submission policy, refer to its website or the Federal Register document.